Quick answers
- What is Opill?
- Opill is a brand name of Norgestrel, an over-the-counter medicine. The FDA NDC Directory lists 2 Opill products in 1 strength and form.
- Who makes Opill?
- Laboratoire Hra holds the FDA application for Opill (NDA017031, approved October 23, 1973). 1 other company (repackagers or distributors) also list Opill products.
- Is there a generic or store brand of Opill?
- Yes. The FDA NDC Directory lists 2 other products with the same active ingredients, strength and form as a Opill product. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for Opill?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 1 Opill strength and form (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Opill been recalled?
- No recall linked to Opill products (by their NDC code or label) appears in the FDA enforcement reports we use.
What Opill is
Each Opill product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Norgestrel · over-the-counter medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| norgestrel 0.075 mg tablet (oral) | Opill | 2 products, 2 companies | DailyMed |
Its page quotes the Drug Facts label and lists every brand and store brand: Norgestrel →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| NDA017031 | Laboratoire Hra | October 23, 1973 | 2 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| norgestrel 0.075 mg tablet | Brand: Opill | $0.4991–$0.5988 per tablet 2 packages, lowest to highest |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Opill
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Opill products.
- L. Perrigo Company1 product
- Redpharm Drug1 product
Recalls
No recall linked to Opill products (by their NDC code or label) appears in the FDA enforcement reports.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.